Invivyd (IVVD) said Wednesday that it has urged the US Food and Drug Administration to focus on monoclonal antibodies for the prevention of COVID-19 to rebuild Americans' trust in scientific data and public health recommendations.
The company said the citizen petition it filed with the FDA requested a re-evaluation of COVID-19 mRNA vaccines as well as new clinical trials to assess vaccine effectiveness.
Invivyd said it has also asked the US health regulator to make clear that biologics license application approval is appropriate based on serum virus neutralizing antibody titers.
The company's shares rose 7% in recent premarket activity on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.